Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inflexal V immune response study in elderly adults
2011-003188-31Phase 4Completed
- Sponsor
- Crucell
- Start
- Jan 2012
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Inflexal V in influenza, sponsored by Crucell. Primary endpoint: Hemagglutination inhibition immunogenicity at 21 days. Started Jan 2012; status: completed.
02
Drugs
Inflexal V
03
Conditions
influenza
Beyond the preview
Go deeper on 2011-003188-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003188-31.